全文获取类型
收费全文 | 126012篇 |
免费 | 10886篇 |
国内免费 | 8163篇 |
专业分类
耳鼻咽喉 | 1021篇 |
儿科学 | 1561篇 |
妇产科学 | 2323篇 |
基础医学 | 14814篇 |
口腔科学 | 2061篇 |
临床医学 | 16410篇 |
内科学 | 20697篇 |
皮肤病学 | 1448篇 |
神经病学 | 6874篇 |
特种医学 | 4297篇 |
外国民族医学 | 70篇 |
外科学 | 13093篇 |
综合类 | 18913篇 |
现状与发展 | 24篇 |
一般理论 | 5篇 |
预防医学 | 7814篇 |
眼科学 | 3663篇 |
药学 | 12780篇 |
115篇 | |
中国医学 | 6038篇 |
肿瘤学 | 11040篇 |
出版年
2024年 | 345篇 |
2023年 | 1822篇 |
2022年 | 4661篇 |
2021年 | 5862篇 |
2020年 | 4222篇 |
2019年 | 4062篇 |
2018年 | 4129篇 |
2017年 | 3691篇 |
2016年 | 3460篇 |
2015年 | 5213篇 |
2014年 | 6535篇 |
2013年 | 6094篇 |
2012年 | 8904篇 |
2011年 | 9763篇 |
2010年 | 5951篇 |
2009年 | 4739篇 |
2008年 | 6508篇 |
2007年 | 6504篇 |
2006年 | 6545篇 |
2005年 | 6493篇 |
2004年 | 4465篇 |
2003年 | 4216篇 |
2002年 | 3562篇 |
2001年 | 3226篇 |
2000年 | 3309篇 |
1999年 | 3451篇 |
1998年 | 2243篇 |
1997年 | 2168篇 |
1996年 | 1564篇 |
1995年 | 1457篇 |
1994年 | 1267篇 |
1993年 | 819篇 |
1992年 | 1227篇 |
1991年 | 1075篇 |
1990年 | 931篇 |
1989年 | 823篇 |
1988年 | 712篇 |
1987年 | 668篇 |
1986年 | 508篇 |
1985年 | 463篇 |
1984年 | 249篇 |
1983年 | 178篇 |
1982年 | 118篇 |
1981年 | 116篇 |
1980年 | 76篇 |
1979年 | 120篇 |
1978年 | 59篇 |
1976年 | 52篇 |
1975年 | 55篇 |
1974年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 了解我国老年人中医证候分布特征,为中医药辨治老年人提供参考依据。方法 系统检索中国知识基础设施(CNKI)、中文科技期刊数据库(CCD)、万方数据资源系统数据库(CSPD),纳入研究对象为老年人的临床流行病学调查研究文献,对其调查目的、调查疾病及调查结果等进行描述统计。结果 ①最终纳入168篇文献,其中2010至2020年之间发表138篇(82.14%);调查地区涵盖全国28个省市自治区,共纳入43948例老年人,累计覆盖340个研究中心;②主要研究结果显示,老年人中医证候阴虚阳亢证(10.05%)>血瘀证(9.5%)>痰浊(湿)证(8.91%)>阴阳两虚证(4.98%)>痰瘀互结证(4.96%);单元证分布阴虚证(14.70%)>痰证(11.22%)>气虚证(7.15%)>肾虚证(4.72%)>血瘀证(4.18%);涉及病变脏腑肾>肝>脾>肺>心。结论 根据统计结果,可以看出老年人证候分布虚证多于实证,虚证中又以阴虚证、气虚证最为多见,实证常见血瘀证、痰浊(湿)证等,且多见痰瘀互结证;老年人五脏皆损,其中又以肾、肝、脾功能失调最为突出。 相似文献
2.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
3.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
4.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
5.
Forgiveness has been found one substantial element in the recovery for women survivors from intimate partner violence following the termination of the abusive relationship. To further investigate the details of forgiveness in this specific context, the present study explored the process of forgiveness using grounded theory. In-depth and semi-structured interviews were conducted with 25 Chinese women survivors of IPV. The findings suggest that forgiveness is a strength-based process including empowerment, transformation, and integration phases. In the empowerment phase, survivors obtain strength at the intrapersonal, behavioural, and interpersonal levels. In the transformation phase, survivors complete cognitive transformation for their IPV experiences and emotional transformation towards former partners. In the integration phase, survivors—now freed from the past—reflect upon and apply the changes they have undergone. Two trajectories in the process were found. One trajectory is going through stages sequentially and the other trajectory is experiencing back and forth between empowerment and transformation stages before moving into the integration stage. The study's findings broaden our knowledge of the strength-based forgiveness process that women survivors of IPV undergo during recovery. Practitioners and policymakers could develop programmes and policies that support forgiveness by holistically facilitating their recovery and empowerment like assistance in dealing with life difficulties and promoting their reconnection with social networks. To improve the transferability and validity of the findings, the forgiveness of survivors of IPV could be explored in a diverse sample (e.g., survivors with low educational background or live in the rural area). 相似文献
6.
7.
8.
10.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 下载免费PDF全文